InterPAD - DETAILS

Vorinostat, 149647-78-9, SAHA, suberoylanilide hydroxamic acid, Zolinza, N-hydroxy-N'-phenyloctanediamide, N1-hydroxy-N8-phenyloctanediamide, Suberanilohydroxamic acid, MK-0683, MK0683, Vorinostat (SAHA, MK0683), Octanediamide, N-hydroxy-N'-phenyl-, OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE, Vorinostat (SAHA), CCRIS 8456, N-Hyrdroxy-N'-phenyloctanediamide, NSC-701852, SHH, C14H20N2O3, CHEMBL98, MFCD00945317, NSC-748799, NSC-759852, 58IFB293JI, DTXSID6041133, CHEBI:45716, WIN64652, NSC701852, SAHA cpd, NCGC00168085-01, NCGC00168085-02, Vorinostat [USAN], Zolinza (TN) (Merck), N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide, DTXCID4021133, N'-hydroxy-N-phenyloctanediamide, Vorinostat MSD, SMR000486344, Zolinza (TN), CAS-149647-78-9, SR-05000000373, Vorinostat (JAN/USAN), Vorinostat [USAN:INN], MK 0683, vorinostatum, UNII-58IFB293JI, SKI390, HSDB 7930, 4lxz, Vorinostat(SAHA), Zolinza; SAHA, N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide hydroxamic acid, 1zz1, VORINOSTAT [MI], SW-064652, VORINOSTAT [INN], VORINOSTAT [JAN], 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide, VORINOSTAT [VANDF], cid_5311, SCHEMBL9018, VORINOSTAT [MART.], VORINOSTAT [WHO-DD], Suberoylanilidehydroxamic Acid, MLS001065855, MLS006011941, GTPL6852, VORINOSTAT [ORANGE BOOK], BDBM19149, Vorinostat (SAHA; MK0683), n-hydroxy-n'-phenyl-octanediamide, SUBERANILOHYDROXAMINIC ACID, 1t69, N-hydroxy-N''-phenyloctanediamide, BCPP000018, HMS2219L20, HMS3264D20, HMS3327C12, HMS3426G03, HMS3650D09, HMS3654G11, HMS3715E22, HMS3745M03, Pharmakon1600-01502267, BCP01858, EX-A2745, SAHA, >=98% (HPLC), Vorinostat,SAHA,Zolinza,MK-0683, Tox21_112605, Tox21_113623, Vorinostat,CAS:149647-78-9, HB1396, NSC748799, NSC759852, Octanediamide, N1-hydroxy-N8-phenyl, s1047, SK1390, AKOS015966648, Octanediamide, N1-hydroxy-N8-phenyl-, Tox21_112605_1, AC-1923, CCG-208659, CS-0589, DB02546, DG-0025, NSC 701852, NSC 748799, NSC 759852, SB17319, NCGC00168085-03, NCGC00168085-04, NCGC00168085-05, NCGC00168085-13, BP-25652, BP-30216, BV164560, HY-10221, SY009383, AM20030018, FT-0650593, H1388, NS00068618, SW199536-4, D06320, EN300-120641, AB00375377-07, AB00375377-08, AB00375377-09, AB01644613_25, A808935, Q905901, Vorinostat, SAHA, suberoylanilide hydroxamic acid, SR-05000000373-2, SR-05000000373-6, SR-05000000373-8, W-201327, BRD-K81418486-001-01-2, BRD-K81418486-001-10-3, BRD-K81418486-001-12-9, BRD-K81418486-001-13-7, BRD-K81418486-001-17-8, BRD-K81418486-001-18-6, Z1530532755, N-Hydroxy-N inverted exclamation mark -phenyloctanediamide, MK0683 , suberoylanilide hydroxamic acid , SAHA, 1227736-21-1

No.	Title	Href
1	Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017 Nov;6(11):2673-2685. doi: 10.1002/cam4.1209.	`Click`
2	The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer. Biochem Pharmacol. 2023 Oct;216:115807. doi: 10.1016/j.bcp.2023.115807.	`Click`
3	SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2. Anticancer Res. 2020 Jan;40(1):9-26. doi: 10.21873/anticanres.13922.	`Click`
4	Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitorsInhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2016 Sep 9;478(1):227-233. doi: 10.1016/j.bbrc.2016.07.063.	`Click`

No.

Title

Href

Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med. 2017 Nov;6(11):2673-2685. doi: 10.1002/cam4.1209.

Click

The novel small molecule BH3 mimetic nobiletin synergizes with vorinostat to induce apoptosis and autophagy in small cell lung cancer. Biochem Pharmacol. 2023 Oct;216:115807. doi: 10.1016/j.bcp.2023.115807.

Click

SAHA and EGCG Promote Apoptosis in Triple-negative Breast Cancer Cells, Possibly Through the Modulation of cIAP2. Anticancer Res. 2020 Jan;40(1):9-26. doi: 10.21873/anticanres.13922.

Click

Inhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitorsInhibition of SRC-3 enhances sensitivity of human cancer cells to histone deacetylase inhibitors. Biochem Biophys Res Commun. 2016 Sep 9;478(1):227-233. doi: 10.1016/j.bbrc.2016.07.063.

Click

Name	Vorinostat
PubChem CID	5311
Molecular Weight	264.32g/mol
Synonyms	Vorinostat, 149647-78-9, SAHA, suberoylanilide hydroxamic acid, Zolinza, N-hydroxy-N'-phenyloctanediamide, N1-hydroxy-N8-phenyloctanediamide, Suberanilohydroxamic acid, MK-0683, MK0683, Vorinostat (SAHA, MK0683), Octanediamide, N-hydroxy-N'-phenyl-, OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE, Vorinostat (SAHA), CCRIS 8456, N-Hyrdroxy-N'-phenyloctanediamide, NSC-701852, SHH, C14H20N2O3, CHEMBL98, MFCD00945317, NSC-748799, NSC-759852, 58IFB293JI, DTXSID6041133, CHEBI:45716, WIN64652, NSC701852, SAHA cpd, NCGC00168085-01, NCGC00168085-02, Vorinostat [USAN], Zolinza (TN) (Merck), N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide, DTXCID4021133, N'-hydroxy-N-phenyloctanediamide, Vorinostat MSD, SMR000486344, Zolinza (TN), CAS-149647-78-9, SR-05000000373, Vorinostat (JAN/USAN), Vorinostat [USAN:INN], MK 0683, vorinostatum, UNII-58IFB293JI, SKI390, HSDB 7930, 4lxz, Vorinostat(SAHA), Zolinza; SAHA, N1-hydroxy-N8-phenyl-octanediamide, SAHA, Suberoylanilide hydroxamic acid, 1zz1, VORINOSTAT [MI], SW-064652, VORINOSTAT [INN], VORINOSTAT [JAN], 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide, VORINOSTAT [VANDF], cid_5311, SCHEMBL9018, VORINOSTAT [MART.], VORINOSTAT [WHO-DD], Suberoylanilidehydroxamic Acid, MLS001065855, MLS006011941, GTPL6852, VORINOSTAT [ORANGE BOOK], BDBM19149, Vorinostat (SAHA; MK0683), n-hydroxy-n'-phenyl-octanediamide, SUBERANILOHYDROXAMINIC ACID, 1t69, N-hydroxy-N''-phenyloctanediamide, BCPP000018, HMS2219L20, HMS3264D20, HMS3327C12, HMS3426G03, HMS3650D09, HMS3654G11, HMS3715E22, HMS3745M03, Pharmakon1600-01502267, BCP01858, EX-A2745, SAHA, >=98% (HPLC), Vorinostat,SAHA,Zolinza,MK-0683, Tox21_112605, Tox21_113623, Vorinostat,CAS:149647-78-9, HB1396, NSC748799, NSC759852, Octanediamide, N1-hydroxy-N8-phenyl, s1047, SK1390, AKOS015966648, Octanediamide, N1-hydroxy-N8-phenyl-, Tox21_112605_1, AC-1923, CCG-208659, CS-0589, DB02546, DG-0025, NSC 701852, NSC 748799, NSC 759852, SB17319, NCGC00168085-03, NCGC00168085-04, NCGC00168085-05, NCGC00168085-13, BP-25652, BP-30216, BV164560, HY-10221, SY009383, AM20030018, FT-0650593, H1388, NS00068618, SW199536-4, D06320, EN300-120641, AB00375377-07, AB00375377-08, AB00375377-09, AB01644613_25, A808935, Q905901, Vorinostat, SAHA, suberoylanilide hydroxamic acid, SR-05000000373-2, SR-05000000373-6, SR-05000000373-8, W-201327, BRD-K81418486-001-01-2, BRD-K81418486-001-10-3, BRD-K81418486-001-12-9, BRD-K81418486-001-13-7, BRD-K81418486-001-17-8, BRD-K81418486-001-18-6, Z1530532755, N-Hydroxy-N inverted exclamation mark -phenyloctanediamide, MK0683 , suberoylanilide hydroxamic acid , SAHA, 1227736-21-1
Drug Type	Small molecule
Formula	C₁₄H₂₀N₂O₃
SMILES	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO
InChI	1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)
InChIKey	WAEXFXRVDQXREF-UHFFFAOYSA-N
CAS Number	149647-78-9
ChEMBL ID	CHEMBL98
ChEBI ID	CHEBI:45716
TTD ID	D0E7PQ
Drug Bank ID	DB02546
KEGG ID	D06320
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Pair Name	Pterostilbene, Vorinostat
Partner Name	Pterostilbene
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Expression	HIF1A	hsa3091
	Down-regulation	Expression	IL1B	hsa3553
	Down-regulation	Expression	MTA1	hsa9112
	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
In Vivo Model	Female C57BL/6J mouse homozygous with "floxed" allele of Pten gene were used in this study.
Result	Our study provides preclinical evidence that Pter/SAHA combination treatment inhibits MTA1/HIF-1α tumor-promoting signaling in PCa. The beneficial outcome of combinatorial strategy using a natural agent and an approved drug for higher efficacy and less toxicity supports further development of MTA1-targeted therapies in PCa.

Pair Name	Nobiletin, Vorinostat
Partner Name	Nobiletin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->Apoptosis and autophagy
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BCL-xL	hsa598
	Down-regulation	Expression	BECN1	hsa8678
	Up-regulation	Expression	BID	hsa637
	Up-regulation	Expression	BIM	hsa10018
	Up-regulation	Cleavage	CASP9	hsa842
	Up-regulation	Expression	MAP1LC3B	hsa81631
	Down-regulation	Expression	MCL1	hsa4170
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Phosphorylation	PIK3CA	hsa5290
In Vitro Model	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
	PANC-1	Pancreatic ductal adenocarcinoma	Homo sapiens (Human)	CVCL_0480
	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H69	Lung small cell carcinoma	Homo sapiens (Human)	CVCL_1579
	NCI-H82	Lung small cell carcinoma	Homo sapiens (Human)	CVCL_1591
In Vivo Model	A subcutaneous injection of 5×10⁶ H82 cells was administered into the right flank of each BALB/c nude mouse.
Result	The combination of nobiletin with vorinostat increased histone H3K9 and H3K27 acetylation levels in SCLC mouse tumor tissue and enhanced the expression of the BH3-only proteins BIM and BID. We conclude that nobiletin is a novel natural BH3 mimetic that can cooperate with vorinostat to induce apoptosis and autophagy in SCLC.

Pair Name	Epigallocatechin gallate, Vorinostat
Partner Name	Epigallocatechin gallate
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	BIRC3	hsa330
Gene Regulation	Up-regulation	Expression	CASP7	hsa840
In Vitro Model	MDA-MB-157	Breast carcinoma	Homo sapiens (Human)	CVCL_0618
	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
	HCC1806	Breast squamous cell carcinoma, acantholytic variant	Homo sapiens (Human)	CVCL_1258
Result	The compounds were able to decrease the expression of cIAP2 while increasing the expression of pro-apoptotic caspase 7. There were also changes in histone modifications, suggesting a role of epigenetic mechanisms in these changes in expression of cIAP2. These changes resulted in an increase in apoptosis. SAHA and EGCG were also capable of limiting TNBC cell migration across a fibronectin (FN) matrix.

Pair Name	Bufalin, Vorinostat
Partner Name	Bufalin
Disease Info	[ICD-11: 2A00-2F9Z]	Solid tumour or cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Up-regulation	Activity	AKT1	hsa207
Gene Regulation	Down-regulation	Expression	BCL2	hsa596
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
Result	These accumulating data might guide development of new breast and lung cancer therapies.